Australasian Life Science Investment Summit
The inaugural Australasian Life Science Investment Summit will attract national and international
investors, comprising angel investors, venture capitalists, fund managers, investment bankers and representatives of superannuation funds. It will also attract the venture capital arms of the major pharmaceutical and biotechnology companies from Australia, the Asia Pacific region, North America and Europe.
One of AusBiotech’s priorities is to stimulate and support investment in Australia’s biotechnology
innovation. One of the most effective ways to achieve this is to develop and manage independent investor meetings that ensure access for the Australian industry to global life science investors, a task even more important in these times of economic duress.
The presenting companies will be a mix of listed companies in late-stage development, private
companies with identified product/opportunities and early-stage commercialisation companies from research institutes and universities.
By invitation only: Investors are invited to register their interest to attend with Glenn Cross gcross@ausbiotech.org
Expressions of interest from presenting companies (public and private) have now closed.
Event Information
Dates: Tuesday, 27 October 2009
Venue: Melbourne Convention and Exhibition Centre,
Clarendon Street, Melbourne
Please click here to view the program
| Confirmed Investors (Australia) | |
|
Acorn Capital |
|
|
AFG Venture Group |
|
|
ANU Connect Ventures Pty Ltd |
|
|
Applied BioSystems |
|
|
Aragon Capital |
|
|
Atrico |
|
|
Australian Ethical Investments |
|
|
AVCAL |
|
|
BioFusion Capital |
|
|
Bioscience Managers |
|
|
BR Angels Pty Ltd |
|
|
Brandon Capital Partners |
|
|
CM Capital Investments |
|
|
E.L. & C. Baillieu Stockbroking |
|
|
East West Capital |
|
|
Fighting Fish Ventures |
|
|
Four Hats Capital Pty Ltd |
|
|
GBS Venture Partners |
|
|
GlaxoSmithKline |
|
|
Grand Lodge Pty Ltd |
|
|
Griffith Enterprise |
|
|
J.P. Morgan Asset Management |
|
|
Kinetic Investment Partners |
|
|
Longreach Capital Pty Ltd |
|
|
Maia Partners |
|
|
Melbourne Angels |
|
|
Merck Sharp & Dohme |
|
|
Novozymes Biopharma |
|
|
Pfizer |
|
|
pharmaBank Pty Ltd |
|
|
POWERflex Corporation |
|
|
Prime Value |
|
|
Queensland Biocapital Fund (QBF) |
|
|
RBS Morgans |
|
|
Scientia Capital |
|
|
Solvay Pharmaceuticals |
|
|
Starfish Ventures |
|
|
State Equity Group |
|
|
Stone Ridge Ventures |
|
|
Strategic Life Sciences |
|
|
Synthon |
|
|
T&J Williams P/L |
|
|
Terra Rossa Capital Pty Ltd |
|
|
The Queensland Institute of Medical Research |
|
|
Titan BioVentures Management |
|
|
TM Ventures |
|
|
Trans Tasman Funds Management |
|
|
Uniseed Management Pty Ltd |
|
|
V2V |
|
|
Victorian Funds Management Corporation |
|
|
Yuuwa Capital LP |
5AM Ventures USA Amgen USA Aquarius Consulting USA Bailard USA BioFrontier Partners Japan BioPacificVentures New Zealand Biotech Healthcare Partners Japan Blueprint Life Science Group USA Boehringer-Ingelheim USA CMEA USA Eli Lilly Inc USA Frazier Healthcare USA Global Life Sciences Capital USA Harbin Gloria Pharmaceuticals Co. Ltd China Industrial Technology Investment Corporation Taiwan Lilly Ventures USA MPM Capital USA Newstar Ventures Ltd USA Novo Nordisk Denmark Orbimed India Ortho Clinical Diagnostics Japan RA Capital USA SMH Capital USA Stern Private Equity Club USA The Trout Group USA
Confirmed Investors (
International)
Development Center for Biotechnology
Taiwan
J. Sagar Associates
India
Pacific Channel Limited
New Zealand
The Channel Group
USA
